Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1010
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 709–720 of 1,010 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

NCT03297775
Status at this site: Recruiting
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 90 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

Cannabidiol and Cannabis Concentrate Users

NCT06575751
Status at this site: Recruiting
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Broad Spectrum Cannabidiol (bsCBD) 400 mg, Broad Spectrum Cannabidiol (bsCBD) 200 mg, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Active, not recruiting Not applicable Interventional

Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder

NCT05396638
Site status not listed — check the official record
View directory record Official record
Conditions
Cannabis Use
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Active, not recruiting Phase 2 Interventional

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

NCT04902703
Status at this site: Recruiting
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Sargramostim, Saline - placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
Site status not listed — check the official record
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acellular Dermal Matrix Investigation in Breast Reconstruction

NCT06456554
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Reconstruction
Interventions
Acellular Dermal Matrix (Cortiva Tissue Matrix)
Device
Lead sponsor
RTI Surgical
Industry
Eligibility
22 Years and older · Female only
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024
Status at this site: Recruiting
View directory record Official record
Conditions
Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

NCT07280065
Status at this site: Recruiting
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder
Interventions
Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version
Device · Behavioral
Lead sponsor
Senseye, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
5
States / cities
Aurora, Colorado • Savannah, Georgia • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Active, not recruiting Not applicable Interventional Results available

PERIGON Pivotal Trial

NCT02088554
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Model 400 aortic valve bioprosthesis
Device
Lead sponsor
Medtronic Cardiac Surgery
Industry
Eligibility
18 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
20
States / cities
Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia

NCT05349630
Site status not listed — check the official record
View directory record Official record
Conditions
Right Ventricular Dysfunction, Hypoxia
Interventions
Ferrous sulfate 325mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 5:33 PM EDT

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.